We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PUREPAC'S EXCLUSIVITY CLAIM TO GENERIC NEURONTIN UPHELD
PUREPAC'S EXCLUSIVITY CLAIM TO GENERIC NEURONTIN UPHELD
January 27, 2004
The FDA’s decision to award Alpharma subsidiary Purepac 180-day marketing exclusivity for a generic version of Pfizer’s epilepsy drug Neurontin (gabapentin) has been upheld by a federal appeals court.